Industry·
Isomorphic Labs Secures $5 Billion to Advance AI‑Driven Drug Candidates to Clinical Trials
The DeepMind spin‑out closed a $5 billion Series C round led by Greenoaks and Sequoia, with participation from Andreessen Horowitz and existing backers. The capital will accelerate its AI drug‑design engine and expand into new therapeutic areas.

Isomorphic Labs, the AI‑focused drug discovery platform spun out of Google DeepMind in 2021, has raised a $5 billion Series C round. The financing was co‑led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz joining existing shareholders such as GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
The company’s core technology builds on the AlphaFold protein‑folding breakthrough, employing a suite of simulation models that explore chemical space to design novel drug candidates. Isomorphic reports positive preclinical results in oncology and immunology and has secured partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Why it matters for GPU / AI infrastructure
- Training and inference for large‑scale molecular simulation models demand massive GPU clusters, driving demand for high‑density compute.
- Scalable AI‑drug pipelines create recurring workloads that justify long‑term GPU cloud contracts.
- Advances in protein‑structure prediction push the frontier of model size, reinforcing the need for next‑generation accelerator hardware.
The fresh capital will be used to further develop the drug‑design engine, broaden the therapeutic portfolio and move lead programs into clinical testing, positioning Isomorphic as a flagship workload for AI‑accelerated infrastructure.
- aigpu
- ai gpu
- ai gpu cloud
- aigpu dubai
- drug discovery
- alphafold
- deepmind
- biotech
By AiGpu Editorial · Editorial rewrite based on public reporting (TechCrunch AI)
← All articles